UK Markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.7999+0.0284 (+3.68%)
As of 01:49PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.65
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 319.8700
52-week low 30.7321
50-day moving average 32.1968
200-day moving average 310.4752

Share statistics

Avg vol (3-month) 3765.79k
Avg vol (10-day) 3599.54k
Shares outstanding 532.32M
Implied shares outstanding 6N/A
Float 823.24M
% held by insiders 116.06%
% held by institutions 158.64%
Shares short (28 Apr 2022) 43.69M
Short ratio (28 Apr 2022) 414.05
Short % of float (28 Apr 2022) 413.55%
Short % of shares outstanding (28 Apr 2022) 411.27%
Shares short (prior month 30 Mar 2022) 43.25M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin 0.00%
Operating margin (ttm)-481.87%

Management effectiveness

Return on assets (ttm)-33.88%
Return on equity (ttm)-81.47%

Income statement

Revenue (ttm)18.26M
Revenue per share (ttm)0.59
Quarterly revenue growth (yoy)43.90%
Gross profit (ttm)-42.11M
EBITDA -87.33M
Net income avi to common (ttm)-89.76M
Diluted EPS (ttm)-2.6670
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)146.4M
Total cash per share (mrq)4.47
Total debt (mrq)7.33M
Total debt/equity (mrq)8.31
Current ratio (mrq)8.46
Book value per share (mrq)3.47

Cash flow statement

Operating cash flow (ttm)-64.35M
Levered free cash flow (ttm)-41.44M